• 1
    Harbut RE, Correll GE. Successful treatment of a nine-year case of complex regional pain syndrome type-I (reflex sympathetic dystrophy) with intravenous ketamine-infusion therapy in a warfarin-anticoagulated adult female patient. Pain Med 2002;3: 14755.DOI: 10.1046/j.1526-4637.2002.02029.x
  • 2
    Mendell LM. Physiological properties of unmyelinated fiber projection to the spinal cord. Pain 1966;41: 30921.
  • 3
    Pockett S. Spinal cord synaptic plasticity and chronic pain. Anesth Analg 1995;80: 1739.DOI: 10.1097/00000539-199501000-00026
  • 4
    Mannion RJ, Woolf CJ. Pain Mechanisms and Management: A Central Perspective. Clin J Pain 2000;16(3 suppl):S14456.DOI: 10.1097/00002508-200006000-00008
  • 5
    Carpenter KJ, Dickenson AH. NMDA receptors and pain—hopes for novel analgesics. Reg Anesth Pain Med 1999;24: 5068.
  • 6
    Ahmad M, Ackerman WE, Munir MA, Saleem M. NMDA receptor antagonists. Recent advances in chronic pain. Pain Clinic 2001;April:2531.
  • 7
    Bennett GJ. Update on the neurophysiology of pain transmission and modulation: Focus on the NMDA-receptor. J Pain Symptom Manage 2000;19(1 suppl):S26.
  • 8
    Woolf CJ, Thompson SWN. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation: Implications for the treatment of post-injury pain hypersensitivity states. Pain 1991;44: 2939.DOI: 10.1016/0304-3959(91)90100-C
  • 9
    Fisher K, Coderre TJ, Hagen NA. Targeting the N-methyl-D-aspartate receptor for chronic pain management: Preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage 2000;20: 35873.DOI: 10.1016/S0885-3924(00)00213-X
  • 10
    Sher MH. Slow dose ketamine—a new technique. Anaesth Intensive Care 1980;8: 35961.
  • 11
    Pandit SK, Kothary SP, Kumar SM. Low dose intravenous infusion technique with ketamine. Amnesic, analgesic and sedative effects in human volunteers. Anaesthesia 1980;35: 66975.
  • 12
    Ito Y, Ichiyanagi K. Post-operative pain relief with ketamine infusion. Anaesthesia 1974;29: 2226.
  • 13
    Clausen L, Sinclair DM, Van Hasselt CH. Intravenous ketamine for postoperative analgesia. S Afr Med J 1975;49: 143740.
  • 14
    Sang CN. NMDA-receptor antagonists in neuropathic pain: Experimental methods to clinical trials. J Pain Symptom Manage 2000;19(1 suppl):S215.DOI: 10.1016/S0885-3924(99)00125-6
  • 15
    Backonja M, Arndt G, Gombar KA, Check B, Zimmermann M. Response of chronic neuropathic pain syndromes to ketamine: A preliminary study. Pain 1994;56: 517.
  • 16
    Eide PK, Jorum E, Stubhaug A, Bremnes J, Breivik H. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: A double-blind, cross-over comparison with morphine and placebo. Pain 1994;58: 34754.DOI: 10.1016/0304-3959(94)90129-5
  • 17
    Klepstad P, Borchgrevink PC. Four years’ treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia. Acta Anaesthesiol Scand 1997;41: 4226.
  • 18
    Hoffmann V, Coppejans H, Vercauteren M, Adriaensen H. Successful treatment of postherpetic neuralgia with oral ketamine. Clin J Pain 1994;10: 2402.
  • 19
    Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997;48: 12128.
  • 20
    Sang CN, Parada S, Booher S, et al. A double blinded randomized controlled trial of dextromethorphan versus memantine versus placebo in subjects with painful diabetic neuropathy and postherpetic neuralgia. Presented at the 16th Annual scientific meeting of the American Pain Society. San Diego, CA, November, 1997.
  • 21
    Kinoshita Y, Takakura K, Yanagimoto M, Fujibayashi T, Sugiura Y, Goto Y. Evaluation of ketamine infusion treatment for patients with chronic pain. Hokuriku J Anesthesiol 1997;31: 1114.
  • 22
    Tsuneyoshi I, Gushiken T, Kanmura Y, Yoshimura N. Changes in pain intensity of post-herpetic neuralgia following intravenous injections of ketamine hydrochloride. J Anesth 1999;13: 535.DOI: 10.1007/s005400050023
  • 23
    Wong CS, Shen TT, Liaw WJ, Cherng CH, Ho ST. Epidural coadministration of ketamine, morphine and bupivacaine attenuates post-herpetic neuralgia—a case report. Acta Anaesthesiol Sin 1996;34: 1515.
  • 24
    Nikolajsen L, Hansen CL, Nielsen J, Keller J, Arendt-Nielsen L, Jensen TS. The effect of ketamine on phantom pain: A central neuropathic disorder maintained by peripheral input. Pain 1996;67: 6977.DOI: 10.1016/0304-3959(96)03080-1
  • 25
    Nikolajsen L, Hansen PO, Jensen TS. Oral ketamine therapy in the treatment of postamputation stump pain. Acta Anaesthesiol Scand 1997;41: 4279.
  • 26
    Mitchell AC. An unusual case of chronic neuropathic pain responds to an optimum frequency of intravenous ketamine infusions. J Pain Symptom Manage 2001;21: 4436.DOI: 10.1016/S0885-3924(01)00253-6
  • 27
    Bennett GJ, Maleki J. The multiplicity of neuropathic pain sensations. Pain Forum 1998;7: 2435.
  • 28
    Maleki J. “Sensitization”: Is there a cure? Pain Med 2002;3: 2947.DOI: 10.1046/j.1526-4637.2002.00342.x
  • 29
    Kiefer RT, Rohr P, Unertl K, Altemeyer KH, Grothusen J, Schwartzman RJ. Recovery from intractable complex regional pain syndrome type-I (RSD) under high dose intravenous ketamine-midazolam sedation. Neurology 2002;58(suppl 3):A-474.
  • 30
    Kiefer RT, Rohr P, Ploppa A, Unertl K, Schwartzman RJ. Is high dosed ketamine a therapeutic option for severe intractable Complex Regional Pain Syndrome? Anesthesiology 2003;99: A1008.
  • 31
    Correll GE, Muir JJ, Harbut RE. Use of ketamine infusion in patients with complex regional pain syndrome. J Pain 2002;3(suppl):S17.
  • 32
    Low PA, Wilson PR, Sandroni P, Willner CL, Chelimsky TC. Clinical characteristics of patients with reflex sympathetic dystrophy. In: Jaenig W, Stanton-Hicks M, editors. Reflex sympathetic dystrophy: A reappraisal. Seattle: IASP Press; 1996: 4966.
  • 33
    Finck AD, Samaniego E, Ngai SH. Morphine tolerance decreases the analgesic effects of ketamine in mice. Anesthesiology 1988;68: 397400.
  • 34
    Cai YC, Ma L, Fan GH, Zhao J, Jiang LZ, Pei G. Activation of N-methyl-D-aspartate receptor attenuates acute responsiveness of delta-opioid receptors. Mol Pharmacol 1997;51: 5837.
  • 35
    Smith MT. Neuroexcitatory effects of morphine and hydromorphone: Evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000;27: 5248.DOI: 10.1046/j.1440-1681.2000.03290.x
  • 36
    Bartlett SE, Cramond T, Smith MT. The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex. Life Sci 1994;54: 68794.
  • 37
    Labella FS, Pinsky C, Havlicek V. Morphine derivatives with diminished opiate receptor potency show enhanced central excitatory activity. Brain Res 1979;174: 26371.DOI: 10.1016/0006-8993(79)90849-7
  • 38
    Wright AW, Mather LE, Smith MT. Hydromorphone-3-glucuronide: A more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 2001;69: 40920.DOI: 10.1016/S0024-3205(01)01133-X
  • 39
    Moran TD, Smith PA. Morphine-3beta-D-glucuronide suppresses inhibitory synaptic transmission in rat substantia gelatinosa. J Pharmacol Exp Ther 2002;302: 56876.DOI: 10.1124/jpet.102.035626
  • 40
    Hemstapat K, Monteith GR, Smith D, Smith MT. Morphine-3-glucuronide's neuro-excitatory effects are mediated via indirect activation of N-methyl-D-aspartic acid receptors: Mechanistic studies in embryonic cultured hippocampal neurones. Anesth Analg 2003;97: 494505.DOI: 10.1213/01.ANE.0000059225.40049.99
  • 41
    Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989;244: 13602.
  • 42
    Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, and Sesma MA. NMDA antagonist neurotoxicity: Mechanism and prevention. Science 1991;254: 15158.
  • 43
    Jevtovic-Todorovic V, Wozniak DF, Benshoff ND, Olney JW. A comparative evaluation of the neurotoxic properties of ketamine and nitrous oxide. Brain Res 2001;895: 2647.DOI: 10.1016/S0006-8993(01)02079-0
  • 44
    Ellison G. Competitive and non-competitive NMDA antagonists induce similar limbic degeneration. Neuroreport 1994;5: 268892.
  • 45
    Fix AS, Long GG, Wozniak DF, Olney JW. Pathomorphologic effects of N-methyl-D-aspartate antagonists in the rat posterior cingulate/retrosplenial cerebral cortex: A review. Drug Dev Res 1994;24: 14752.
  • 46
    Corso TD, Sesma MA, Tenkova TI, Der TC, Wozniak DF, Farber NB, Olney JW. Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Res 1997;752: 114.
  • 47
    Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MBJr, Charney DS. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51: 199214.
  • 48
    Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997;17: 14150.DOI: 10.1016/S0893-133X(97)00036-5
  • 49
    Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999;20: 10618.DOI: 10.1016/S0893-133X(98)00067-0
  • 50
    Jevtovic-Todorovic V, Olney JW. Neuroprotective agents. In: Evers AS, Mayes M, editors. Anesthetic pharmacology, physiologic principles and clinical practice. Philadelphia: Churchill Livingstone; 2004: 55772.
  • 51
    Farber NB, Foster J, Duhan NL, Olney JW. Alpha 2 adrenergic agonists prevent MK-801 neurotoxicity. Neuropsychopharmacology 1995;12: 3479.
  • 52
    Newcomer JW, Farber NB, Selke G, Melson AK, Jevtovic-Todorovic V, Olney JW. Guanabenz effects on NMDA antagonist-induced mental symptoms in humans. Soc Neurosci Abstr 1998;24: 525.
  • 53
    Farber NB, Kim SH, Dikranian K, Jiang XP, Heinkel C. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry 2002;7: 3243.DOI: 10.1038/
  • 54
    Levanen J, Makela ML, Scheinin H. Dexmedetomidine premedication attenuates ketamine-induced cardiostimulatory effects and postanesthetic delirium. Anesthesiology 1995;82: 111725.DOI: 10.1097/00000542-199505000-00005
  • 55
    Handa F, Tanaka M, Nishikawa T, Toyooka H. Effects of oral clonidine premedication on side effects of intravenous ketamine anesthesia: A randomized, double-blind placebo-controlled study. J Clin Anesth 2000;12: 1924.DOI: 10.1016/S0952-8180(99)00131-2
  • 56
    Kim SH, Price MT, Olney JW, Farber NB. Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and α2-adrenergic agonists. Mol Psychiatry 1999;4: 34452.DOI: 10.1038/
  • 57
    Lee YW, Yaksh TL. Analysis of drug interaction between intrathecal clonidine and MK-801 in peripheral neuropathic pain rat model. Anesthesiology 1995;82: 7418.DOI: 10.1097/00000542-199503000-00016
  • 58
    Jevtovic-Todorovic V, Wozniak DF, Powell S, Nardi A, Olney JW. Clonidine potentiates the neuropathic pain-relieving action of MK-801 while preventing its neurotoxic and hyperactivity side effects. Brain Res 1998;781: 20211.DOI: 10.1016/S0006-8993(97)01247-X